Novartis Q4 sales, core net income trail expectations
Switzerland's Novartis said delays of two blockbuster hopefuls - heart drug Leqvio that cost it $10 billion and $2.1m-per-patient Zolgensma - remain in regulators' hands, dragging on sales already hit by the pandemic.
Business
• 26 Jan 21
